Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM.
Hoang T, et al. Among authors: larson mm.
Invest New Drugs. 2014 Feb;32(1):195-9. doi: 10.1007/s10637-013-9980-5. Epub 2013 Jun 1.
Invest New Drugs. 2014.
PMID: 23728919
Free PMC article.
Clinical Trial.